A new drug blocks DHT at the scalp — not in the body. That distinction is everything.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
6:49
From Root to Ritual by Laritelle Organic.
For thirty years, the pharmaceutical approach to androgenetic alopecia has relied on one systemic DHT-blocking drug: finasteride. It works by inhibiting 5-alpha reductase throughout the body — reducing DHT production systemically, which reduces DHT at the follicle, which slows the miniaturisation process. It is effective. It is also contraindicated in women of reproductive age, produces sexual sid...
Read the full article: https://laritelleorganic.com/blogs/news/a-new-drug-blocks-dht-at-the-scalp-not-in-the-body-that-distinction-is-everything
For 30 years, the pharmaceutical approach to androgenetic alopecia has relied on one systemic DHT blocking drug, phenasteride. It works by inhibiting five alpha reductus throughout the body, reducing DHT production systemically, which reduces DHT at the follicle, which slows the miniaturization process. It is effective. It is also contraindicated in women of reproductive age, produces sexual side effects in a meaningful proportion of users, and requires continuous use, because the DHT reduction is systemic and disappears when the drug is stopped. The drug's systemic nature was never the goal, it was the consequence of the delivery route. What researchers always wanted was to block DHT at the follicle specifically, locally, without affecting systemic hormone levels. The technology to do that topically, at therapeutic concentration, simply did not exist in pharmaceutical form when phynasteride was developed. Cosmo pharmaceuticals just demonstrated that it does now. Clascoterone, a topical androgen receptor blocker applied directly to the scalp, showed 539% relative improvement in hair count compared to placebo in scalp 1, and 168% in scalp 2, across 1,465 men. If approved, it would be the first scalp treatment that works by blocking DHT right at the hair follicle. The first of its kind, made specifically for male hair loss. The topical route was always the right route, the pharmaceutical industry has just confirmed it with the largest trial dataset ever produced for a top, ICL DHT blocker, the mechanism. Why local DHT blockade is different and better than systemic, DHT drives androgenetic alopecia by binding to androgen receptors in genetically susceptible follicles, specifically the dermal papilla cells, which respond to DHT by producing the miniaturization signals that shorten the N-Agen phase and progressively reduce follicle size. The target is always the androgen receptor in the follicle. Phenasteride reaches it by reducing systemic DHT production, clascoterone reaches it by blocking the receptor directly at the follicle. The distinction has three significant clinical consequences. No systemic hormonal disruption. Phenasterade reduces DHT throughout the body, in the scalp, in the prostate, in the bloodstream, in every tissue that responds to DHT. The sexual side effects that affect an estimated 2-8% of users occur because DHT is suppressed systemically, including in tissues where DHT serves important functions. Clascoderone blocks the androgen receptor locally, at the follicle, without reducing systemic DHT. The follicle doesn't receive the DHT signal, everything else continues receiving it normally. This is not a marginal improvement on phenasteride's side effect profile. It is a mechanistically different approach that eliminates the source of those side effects entirely. Potential for female use phenasteride is contraindicated in women of reproductive age due to teratogenic risk. It is a category X drug in pregnancy. Female H. Air loss is predominantly driven by relative androgen excess and receptor sensitivity rather than absolute DHT elevation, making the systemic 5-alpha reductus inhibition model poorly suited to women's biology. Clascoderone's local androgen receptor blockade is mechanistically more appropriate for female pattern hair loss, addressing sensitivity at the receptor level without systemic hormonal consequences. The current trials enrolled men. Female trials are the logical next step, and the perimenopausal women who represent the majority of those affected by hair loss are the population most likely to benefit from a topical receptor blocker over a systemic DHT suppressor. Precision delivery, the topical advantage. The scalp permeability research we covered this week confirms that the scalp is a highly absorptive surface. Topically applied compounds reach the follicle through both the follicular route and transdermal absorption into the dermal vascular network. A compound designed to block the androgen receptor, applied topically to the scalp daily, is delivering its effect precisely where it is needed, not throughout the body. Topical delivery is not a compromise form of pharmaceutical delivery. For follicle targeted treatment, it is the optimal form. The clascoterone results confirm this at a scale that no previous topical treatment trial has reached. 539%, relative improvement in hair count versus placebo in scalp 1, the largest efficacy signal ever produced in a topical high. R loss trial, 1,465 men enrolled across scalp 1 and scalp 2, the largest topical DHT blocker trial dataset ever assembled, zero systemic hormonal side effects, because the mechanism is local receptor blockade, not systemic DHT reduction. The botanical parallel, the topical DHT inhibition that has always been available. Clascoderone is a synthetic androgen receptor antagonist. The mechanism blocking DHT's interaction with the androgen receptor at the follicle, delivered topically, is new in pharmaceutical form. It is not new in botanical medicine. Several botanical compounds have demonstrated 5 alpha reductus inhibition, or androgen receptor modulation in peer-reviewed research, delivered topically at therapeutic concentration. Botanical compound mechanism evidence. Bringarage, Eclipta alba, 5 alpha reduct inhibition, reduces DHT conversion at follicle level, clinical evidence for hair regrowth. Traditional use across millennia confirmed by modern mechanism research, nettle root, inhibits 5 alpha reductus and binds sex hormone binding globulin, reduces free DHT availability. In vitro 5AR inhibition confirmed, clinical use well established in Europe for androgenic conditions. Saw palmetto, serenoa repens, dual 5AR inhibition, type 1 and 2, broader than phenasteride, which only inhibits type 2 RCT versus phenasteride, showed comparable results with significantly better tolerability profile rosemary, salvia rosmarinus, 5AR inhibition plus IgF 1 upregulation plus microscere.